Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0K4RK
|
||||
Former ID |
DNCL003319
|
||||
Drug Name |
Blinatumomab
|
||||
Synonyms |
AMG 103
|
||||
Drug Type |
Monoclonal antibody
|
||||
Company |
Amgen
|
||||
CAS Number |
CAS 853426-35-4
|
||||
Target and Pathway | |||||
Target(s) | B-lymphocyte antigen CD19 | Target Info | Modulator | [533123] | |
T-cell surface glycoprotein CD3 | Target Info | Modulator | [533123] | ||
NetPath Pathway | IL-7 Signaling Pathway | ||||
PANTHER Pathway | B cell activation | ||||
Pathway Interaction Database | BCR signaling pathway | ||||
References | |||||
Ref 889388 | ClinicalTrials.gov (NCT02013167) Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL) | ||||
Ref 889412 | ClinicalTrials.gov (NCT02393859) Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HR First Relapse B-precursor ALL |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.